Equities

Comera Life Sciences Holdings Inc

CMRA:PKL

Comera Life Sciences Holdings Inc

Actions
  • Price (USD)0.0268
  • Today's Change0.001 / 4.90%
  • Shares traded1.00k
  • 1 Year change-95.42%
  • Beta0.1500
Data delayed at least 15 minutes, as of Jul 05 2024 20:05 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company applies a knowledge of formulation science and technology to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The Company is engaged in developing an internal portfolio of therapeutic product candidates using its proprietary formulation platform, SQore. Its proprietary formulation platform, SQore, is designed to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. Its product programs include CLS-001, a preclinical stage bio better for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage bio better for various oncology indications. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to its partners’ biologic medicines to deliver enhanced SQ formulations.

  • Revenue in USD (TTM)1.00m
  • Net income in USD-9.35m
  • Incorporated2022
  • Employees12.00
  • Location
    Comera Life Sciences Holdings Inc12 Gill Street, Suite 4650WOBURN 01801United StatesUSA
  • Phone+1 (617) 871-2101
  • Fax+1 (561) 694-1639
  • Websitehttps://www.comeralifesciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Molecular Pharmacology (USA) Ltd0.00-105.18k599.73k0.00---------0.0009-0.00090.00-0.01880.00-------976.60-1,219.29------------------------44.29------
Capstone Therapeutics Corp0.00-358.00k646.20k2.00---------6.58-38.120.00-60.700.00-------113.46141.94-199.60173.06-----------2.92--------52.46------
Pharmagreen Biotech Inc1.56k-500.66k663.65k0.00------425.41-0.0011-0.00110.00-0.00450.0094--3.35---302.10-472.20----11.54---32,096.15--0.0194-71.71--------80.68------
Bluejay Diagnostics Inc0.00-9.74m672.69k10.00--0.0595-----61.41-61.410.0010.020.00----0.00-122.06---149.68--------------0.0048---100.00---7.07------
Better Therapeutics Inc0.00-31.57m718.01k54.00---------1.16-1.160.00-0.24490.00----0.00-162.15---378.28-------------15.183.27------1.43------
Respirerx Pharmaceuticals Inc0.00-2.17m803.92k2.00---------0.014-0.0140.00-0.04120.00----0.00-2,255.78-2,491.69---------------2.90---------12.78------
Comera Life Sciences Holdings Inc1.00m-9.35m822.24k12.00------0.8219-0.4901-0.49010.05120.00330.2498--5.0883,367.50-224.98---1,094.30--73.52---900.55------0.00--97.95---237.10------
GlobeStar Therapeutics Corp0.00-1.98m872.19k-----------0.0023-0.00230.00-0.00150.00-------38,103.72-4,657.88-------7,790.20---2,834,410.00---21.00---------31.01------
International Stem Cell Corp7.83m-327.00k907.70k29.00------0.1159-0.0409-0.04090.97850.00451.462.5311.87270,069.00-5.81-29.22-68.13-73.8258.5859.49-3.97-21.010.4672-6.060.9898---4.78-6.8260.42---34.45--
GRI Bio Inc0.00-12.77m947.93k4.00--0.138-----349.68-349.680.0011.380.00----0.00-382.23-192.93-869.57-353.99-------37,650.49---16.800.00-------85.61--29.46--
Data as of Jul 05 2024. Currency figures normalised to Comera Life Sciences Holdings Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.